{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:49:41Z","timestamp":1789818581873,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.humpath.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T04:45:45Z","timestamp":1507956345000},"page":"70-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important"],"prefix":"10.1016","volume":"70","author":[{"given":"Tiansheng","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene P.","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2017.10.002_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.humpath.2017.10.002_bb0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cncr.11083","article-title":"Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor","volume":"97","author":"Chang","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2017.10.002_bb0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ijc.29503","article-title":"Twenty-years experience with de novo metastatic breast cancer","volume":"137","author":"Cortesi","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2017.10.002_bb0020","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2017.10.002_bb0025","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1200\/JCO.2007.14.1168","article-title":"Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer","volume":"26","author":"Dawood","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.10.002_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1006285726561","article-title":"Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients","volume":"56","author":"Insa","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2017.10.002_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10552-011-9859-8","article-title":"Factors associated with mortality after breast cancer metastasis","volume":"23","author":"Jung","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.humpath.2017.10.002_bb0040","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","article-title":"Prognostic factors in 1,038 women with metastatic breast cancer","volume":"19","author":"Largillier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2017.10.002_bb0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","article-title":"Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome","volume":"141","author":"Lobbezoo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2017.10.002_bb0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.prp.2014.01.008","article-title":"Prognostic factors in patients with metastatic breast cancer at the time of diagnosis","volume":"210","author":"Ren","year":"2014","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2017.10.002_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1272\/jnms.81.139","article-title":"Comparison of outcomes between women with de novo stage IV and relapsed breast cancer","volume":"81","author":"Kitagawa","year":"2014","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.humpath.2017.10.002_bb0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/tbj.12717","article-title":"Prognostic factors of survival among women with metastatic breast cancer and impact of primary or secondary nature of disease on survival: a French population-based study","volume":"23","author":"Marshall","year":"2017","journal-title":"Breast J"},{"key":"10.1016\/j.humpath.2017.10.002_bb0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.2015.127","article-title":"Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?","volume":"112","author":"Lobbezoo","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2017.10.002_bb0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10555-016-9636-y","article-title":"Current challenges of metastatic breast cancer","volume":"35","author":"Lim","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.humpath.2017.10.002_bb0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prp.2015.11.003","article-title":"Prognostic factors in advanced breast cancer: race and receptor status are significant after development of metastasis","volume":"212","author":"Ren","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2017.10.002_bb0080","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10552-016-0791-9","article-title":"Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population","volume":"27","author":"Tao","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.humpath.2017.10.002_bb0085","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10549-015-3432-1","article-title":"Racial differences in outcomes for patients with metastatic breast cancer by disease subtype","volume":"151","author":"Vaz-Luis","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2017.10.002_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2017.04.002","article-title":"Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: a multicenter retrospective cohort study","author":"Lambertini","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.humpath.2017.10.002_bb0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-016-4080-9","article-title":"Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed","volume":"161","author":"den Brok","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2017.10.002_bb0100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-014-2916-8","article-title":"Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer","volume":"145","author":"Yardley","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2017.10.002_bb0105","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra1204892","article-title":"The implications of clonal genome evolution for cancer medicine","volume":"368","author":"Aparicio","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2017.10.002_bb0110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nature08489","article-title":"Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution","volume":"461","author":"Shah","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2017.10.002_bb0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.breast.2013.10.005","article-title":"Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy","volume":"23","author":"Rossi","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.humpath.2017.10.002_bb0120","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.humpath.2015.07.019","article-title":"Characterization of estrogen receptor\u2013negative\/progesterone receptor\u2013positive breast cancer","volume":"46","author":"Shen","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2017.10.002_bb0125","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1200\/JCO.1992.10.8.1284","article-title":"Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective southwest oncology group study","volume":"10","author":"Ravdin","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.10.002_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12282-011-0320-3","article-title":"Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer","volume":"20","author":"Kawano","year":"2013","journal-title":"Breast Cancer"},{"key":"10.1016\/j.humpath.2017.10.002_bb0135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.prp.2016.09.007","article-title":"Clinicopathologic factors associated with de novo metastatic breast cancer","volume":"212","author":"Shen","year":"2016","journal-title":"Pathol Res Pract"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717303611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717303611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T18:59:55Z","timestamp":1535309995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817717303611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":27,"alternative-id":["S0046817717303611"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2017.10.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2017.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}